TQB3122
/ Sino Biopharm
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 09, 2025
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3122 Capsules in Subjects With Advanced Malignant Tumors
(clinicaltrials.gov)
- P1 | N=86 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1 trial • Oncology • Solid Tumor
August 11, 2025
APPLICATION FOR CLINICAL TRIAL OF TQB3122 “PARP1 INHIBITOR” ACCEPTED BY NMPA
(Sino Biopharm Press Release)
New trial • Solid Tumor
1 to 2
Of
2
Go to page
1